FDA Reviewing Chantix Postmarketing Data On Suicide, Erratic Behavior
This article was originally published in The Pink Sheet Daily
Executive Summary
Early communication by the agency follows one case of erratic behavior leading to the death of a patient using the smoking cessation drug.